It also reduced total cholesterol and triglyceride levels and increased the high-density lipoprotein, HDL (231)
Since late 2023, the FDA has restricted 19 peptides and taken enforcement action against 5+ vendors
GLP-1 receptor agonists CVOTs with liraglutide, dulaglutide and semaglutide demonstrate improved CV outcomes, compared to placebo, in people with type 2 diabetes with established ASCVD or with risk factors for this, including DKD (Marso et al, 2016a
Knauf C, Cani PD, Kim DH, Iglesias MA, Chabo C, Waget A, Colom A, Rastrelli S, Delzenne NM, Drucker DJ, Seeley RJ, Burcelin R (2008 Oct) Role of central nervous system glucagon-like Peptide-1 receptors in enteric glucose sensing
Uncovering the trimethylamine-producing bacteria of the human gut microbiota